New protein injection shows promise in early Alzheimer's trial
NCT ID NCT06489015
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-phase study tests a lab-made protein (recombinant human serum albumin) in 30 people with mild to moderate Alzheimer's. Participants receive one of three doses to check safety and any effect on thinking skills. The goal is to see if this treatment can help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Medical College & Affiliated Hospital Of Jiujiang University
Jiujiang, Jiangxi, 332000, China
-
Luoyang Third People's Hospital
Luoyang, Henan, 471002, China
-
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, 200000, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
-
Wuhan Union Hospital of China
Wuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping the brain to boost memory and mood in Alzheimer's
- Tailored sound waves may sharpen the mind
- Blood test could revolutionize Alzheimer's diagnosis, reducing need for spinal taps and scans
- Blood test could revolutionize Alzheimer's diagnosis at your Doctor's office
- Pink noise at night may boost memory in early Alzheimer's
- Simple blood test could spot Alzheimer's before symptoms worsen